Genprex Receives Formal Nasdaq Delisting Notice, Ineligible for Standard Compliance Period
GNPX is trading near its 52-week low of $0.624 (3.1% above the low) on light trading volume (0.3× avg).
Summary
Genprex, Inc. received a formal delisting notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period due to a recent reverse stock split.
Key Events · Corporate Governance and Compliance · GNPX
-
Formal Delisting Notice Received
Genprex received a letter from Nasdaq on June 10, 2026, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.
-
Ineligible for Compliance Period
Due to a reverse stock split effected on October 21, 2025, Nasdaq determined the company is not eligible for the standard 180-day compliance period.
-
Intent to Request Hearing
Genprex intends to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action pending the hearing.
-
Potential for Another Reverse Split
The company may consider another reverse stock split to regain compliance, a measure for which shareholders were already asked to approve in April 2026.
Analysis · GNPX · Life Sciences
This 8-K confirms Genprex has received a formal delisting notice from Nasdaq, a critical development following previous warnings and shareholder requests for another reverse stock split. The company's ineligibility for a standard compliance period, due to a prior reverse split in October 2025, significantly escalates the risk. While Genprex intends to request a hearing, there is no guarantee of continued listing, which could severely impact its ability to raise capital and its stock price, especially given its existing "going concern" warning.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 41.1% of the 387 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNPX was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.62 to $55.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.